- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Lupin Limited — Updates, 01-07-2026: Press Release
01-07-2026 | 04:44 pm
01-07-2026 | 04:44 pm
Lupin secures EMA approval for NaMuscla®, expanding its use for myotonia treatment to children and adolescents across Europe. This significant development, including new dosage strengths, broadens market access and addresses a key unmet medical need.
No comments yet. Be the first to comment!